QT Medical

Executive Summary

QT Medical, founded in 2015 and based in Irvine, CA, is a medical device company focused on transforming electrocardiogram (ECG) testing. Its core innovation is a system that uses a single-use sensor and a mobile recorder to reduce lead placement time by up to 70%, enabling hospital-grade 12-lead ECGs to be performed outside traditional clinical settings. This technology addresses a critical bottleneck in cardiovascular diagnostics: the complexity and time required for standard ECG lead placement, which often limits accessibility in telemedicine, home care, and emergency situations. By simplifying the process without compromising accuracy, QT Medical aims to democratize ECG testing, making it faster and more convenient for patients and providers alike. The company's value proposition aligns with the growing shift toward remote patient monitoring and decentralized healthcare. The ability to capture high-quality ECGs in non-clinical environments could significantly improve early detection of cardiac arrhythmias, ischemia, and other heart conditions. While specific funding and revenue figures are not disclosed, QT Medical's focus on user-friendly, single-use consumables suggests a strong recurring revenue model. The company is well-positioned to capture a share of the expanding telemedicine and home diagnostics market, provided it achieves regulatory clearances and forms strategic partnerships. Overall, QT Medical's technology has the potential to redefine standard-of-care in ECG acquisition, though commercialization and adoption will be key to its success.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation single-use ECG sensor75% success
• Q4 2026Strategic partnership with a major telemedicine platform (e.g., Teladoc, Amwell)60% success
• Q2 2026Publication of clinical study demonstrating improved diagnostic accuracy versus standard ECG70% success